Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction
Open Access
- 24 September 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 19 (2), 164-173
- https://doi.org/10.1002/lt.23552
Abstract
The purpose of this study was to determine the rate and risk factors for the development of irreversible hepatotoxicity after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) and synthetic hepatic dysfunction. Two hundred fifty-one consecutive patients with HCC and hepatic dysfunction who underwent 443 TACE procedures from 2005 to 2010 were retrospectively reviewed. The included patients met one of the following criteria: a pre-TACE bilirubin level ≥ 2 mg/dL, an international normalized ratio (INR) > 1.5, a creatinine level > 1.2 mg/dL, a platelet count ≤ 60,000/mL, a Model for End-Stage Liver Disease (MELD) score > 15, Child-Turcotte-Pugh class B or C, ascites, or portal vein thrombosis. Hepatotoxicity was defined as new or worsening ascites, encephalopathy, or grade 3 or 4 toxicity (bilirubin, aspartate aminotransferase, alanine aminotransferase, creatinine, or INR) according to the National Cancer Institute Common Terminology Criteria for Adverse Events. The rate and risk factors for death or urgent liver transplantation within 6 weeks of TACE and irreversible hepatotoxicity were determined with a generalized estimating equation analysis. Reversible hepatotoxicity developed after 90 procedures (20%) in 78 patients (31%). Irreversible hepatotoxicity developed after 41 procedures (9%) in 37 patients (15%). Six patients (2%) underwent urgent liver transplantation, and 11 (4%) died within 6 weeks of TACE. Patients at increased risk for procedure-related mortality or urgent liver transplantation within 6 weeks of TACE had a baseline serum bilirubin level ≥ 4.0 mg/dL (P = 0.01), an elevated INR (P < 0.001), hypoalbuminemia with an albumin level < 2.0 g/L (P = 0.01), a serum creatinine level > 2.0 mg/dL (P = 0.02), large ascites (P = 0.002), encephalopathy (P = 0.005), or a MELD score ≥ 20 (P < 0.001). In conclusion, TACE can be performed safely in patients with baseline hepatic dysfunction. However, a poor hepatic reserve increases the risk of irreversible hepatotoxicity, which may lead to death or the need for urgent liver transplantation. Liver Transpl 19:164–173, 2013. © 2012 AASLD.Keywords
This publication has 20 references indexed in Scilit:
- Hepatocellular carcinomaThe Lancet, 2012
- Is the treatment of hepatocellular carcinoma on the waiting list necessary?Liver Transplantation, 2011
- Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?Liver Transplantation, 2011
- Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolizationCancer Treatment Reviews, 2011
- Longitudinal Quality of Life Assessment of Patients with Hepatocellular Carcinoma after Primary Transarterial ChemoembolizationJournal of Vascular and Interventional Radiology, 2010
- Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United StatesLiver Transplantation, 2009
- Comparison of MELD and Child-Pugh Scores to Predict Survival after Chemoembolization for Hepatocellular CarcinomaJournal of Vascular and Interventional Radiology, 2004
- Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled TrialsRadiology, 2002
- A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinomaCancer, 2002
- A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular CarcinomaThe New England Journal of Medicine, 1995